| | 
Part, Chapter, Paragraph
1 I, 2. 4 | give volume movements only, i.e. price movements will not
2 I, 2. 5 | from the new member states (i.e. Eastern European countries).
3 I, 2. 6 | tertiary level education (i.e. ISCED levels 5 or 6) in
4 I, 2. 6 | enrolling in ISCED 6 programmes (i.e. those graduating are those
5 I, 2. 10. 4 | a truly internal market, i.e. one of the primary objectives
6 I, 3. 1 | also a demographic factor i.e. the rise in the mean age
7 I, 3. 1 | who turned 50 in 2005 (i.e. they are currently at the
8 I, 3. 1. 0(1)| understood in a macro context, i.e. the relative change that
9 I, 3. 1 | discovering a pregnancy, i.e. the conception rates outside
10 I, 3. 2 | natural population growth (i.e. the number of births minus
11 I, 3. 2 | diminished to 7 percent, i.e. it nearly halved during
12 I, 3. 2 | natural growth at the moment (i.e. a higher number of deaths
13 I, 3. 2 | accommodate 23 million immigrants, i.e. over 7% of their population.
14 I, 3. 2 | total population is large (i.e. 37%). According to GCIM (
15 I, 3. 3 | with the age structure, i.e. the number of individuals
16 II, 4. 1 | quantity and quality of life (i.e. between total longevity
17 II, 4. 2 | Central and Eastern European (i.e. Bulgaria, the Czech Republic,
18 II, 5. 1. 1 | causes of this disease, i.e., hepatitis B and C virus (
19 II, 5. 1. 2 | and close relationships, i.e. all the things we probably
20 II, 5. 1. 3 | various characteristics – i.e. personal, family, professional,
21 II, 5. 1. 4 | know what good care is, i.e. he/she must be informed
22 II, 5. 3. 1 | to the cancer diagnosis (i.e. 1-year, 3-years, 5-years
23 II, 5. 3. 3 | cancer outcome indicators (i.e. incidence, mortality, survival)
24 II, 5. 3. 6 | countries in macro-areas (i.e. Northern, Western, Southern
25 II, 5. 3. 6 | Eastern European countries, i.e those with the lowest level
26 II, 5. 3. 8 | prevalent cancer cases (i.e. increased needs of the elderly
27 II, 5. 3. 8 | over the next 10-20 years (i.e.: European implementation
28 II, 5. 4. 2 | registers are client-based, i.e. they use only a portion
29 II, 5. 4. 2 | available in the first report (i.e. lower extremity amputations
30 II, 5. 4. 4 | risk factor for prevention, i.e. body mass index, increases
31 II, 5. 4. 4 | from scientific evidence, i.e. the measuring of one’s waist
32 II, 5. 4. 6 | requirements of relevance (i.e they should provide relevant
33 II, 5. 5. 3 | The highest risk group (i.e., 20–24-year-old females)
34 II, 5. 5. 3 | admissions due to ICD-10/F20, i.e. the chapter including schizophrenia,
35 II, 5. 5. 3 | portion is even higher – i.e. more than two fifths. According
36 II, 5. 5. 3 | stronger tendency to be obese, i.e. a 1.5 to 4 times increased
37 II, 5. 5. 3 | billion (Euros 36.2 billion) – i.e. over eight times as much.
38 II, 5. 5. 3 | degree of ascertainment, i.e. for the use of registry
39 II, 5. 5. 3 | distribution, biological factors, i.e., differences in environmental
40 II, 5. 5. 3 | year 2005 was €13 billion, i.e., €27 per European inhabitant.
41 II, 5. 5. 3 | are available in Europe, i.e., beta-interferons 1a and
42 II, 5. 5. 3 | sample of European countries (i.e. number of unemployed people
43 II, 5. 5. 3 | of the patient’s status (i.e. the strengthening of MS
44 II, 5. 5. 3 | studies on the economics of (i.e. the cost of illness of)
45 II, 5. 6. 3 | falling, low bone mass, i.e. osteoporosis, and previous
46 II, 5. 6. 3 | that is comprehensible, i.e. 5 to 10 years (Kanis et
47 II, 5. 7. 1 | stage renal disease (ESRD), i.e. the disease stage where
48 II, 5. 7. 1 | spent for ESRD patients, i.e. 0.083% of the general population (
49 II, 5. 7. 3 | Prevalence of stages 3-5 CKD - i.e. the stages showing a higher
50 II, 5. 7. 5 | cardiovascular disease (i.e. those individuals in whom
51 II, 5. 7. 5 | The registry of patients (i.e. The Statistical Yearbook
52 II, 5. 7. 6 | www.healthypeople.gov/), i.e. a document that challenges
53 II, 5. 8. 5 | population at high risk of COPD, i.e. smokers, can reveal the
54 II, 5. 10. 2 | gold standard methodology (i.e food challenge studies and
55 II, 5. 11. 3 | the examining physician (i.e. required only a moisturizer),
56 II, 5. 12. 1 | causes of this disease, i.e., hepatitis B and C virus (
57 II, 5. 12. 2 | change in rate over time (i.e., no joinpoint, which is
58 II, 5. 12. 3 | Southern and Central Europe, i.e. Portugal (38.7/100,000),
59 II, 5. 12. 4 | causes of this disease, i.e., hepatitis B and C virus (
60 II, 5. 12. 6 | very advanced and selected (i.e. comparatively younger) cases,
61 II, 5. 13 | needs) energy-dense food (i.e. food containing large amounts
62 II, 5. 14. 2 | type de services provided i.e. the number of teeth extracted
63 II, 5. 14. 2 | fillings, but not the outcomes, i.e. whether interventions contributed
64 II, 5. 14. 2 | synthesis international articles i.e. Pubmed databases are the
65 II, 5. 14. 3 | collected that dental erosion, i.e. the loss of tooth enamel
66 II, 5. 14. 5 | to specific life-styles – i.e. children or elderly people;
67 II, 5. 15. 3 | established clinically, i.e. by expert clinicians. The
68 II, 6. 3. 1 | costs and indirect costs (i.e. the impact on sectors other
69 II, 6. 3. 2 | broad-spectrum antibiotics, i.e. antibiotics that kill a
70 II, 6. 3. 3 | continued throughout 2005, i.e. a rise in diagnoses in men
71 II, 6. 3. 6 | standardised information, i.e. returning travellers used
72 II, 7. 2. 3 | level of desegregations, i.e. CARE comprises detailed
73 II, 7. 3. 2 | combine all age groups, i.e. young through to old together,
74 II, 7. 4. 5 | and/or consumer services (i.e. tourism services, sports
75 II, 8. 2. 2 | best-corrected” vision, i.e. visual acuity obtained with
76 II, 8. 2. 2 | correction. Presenting vision, i.e. visual activity obtained
77 II, 9 | different age population groups (i.e. mothers at delivery, newborns,
78 II, 9. 1. 1 | proportion of infant deaths – i.e. nearly three-quarters -
79 II, 9. 1. 1 | a mild clinical CP type, i.e. they walk without aids and
80 II, 9. 1. 2 | excluded from other subgroups (i.e. a child with an abdominal
81 II, 9. 1. 2 | folic acid supplementation (i.e. recommending that women
82 II, 9. 2. 2 | outside of the school system i.e. truants and those involved
83 II, 9. 2. 3 | functioning and ability – i.e. the International Classification
84 II, 9. 3. 1 | in early and middle age (i.e. testicular cancer characterized
85 II, 9. 4. 3 | with activity limitations (i.e. about 15 years for men and
86 II, 9. 4. 3 | women than in older men (i.e. individuals >70 years of
87 II, 9. 4. 5 | currently receive formal care, i.e. medical or social services.
88 II, 9. 4. 5 | that structural change - i.e. the creation of single agencies
89 II, 9. 5. 4 | the ‘chain of research’, i.e. hypothesis, diagnostic tools,
90 III, 10. 2. 1 | the recommended approach, i.e. a package of six policies
91 III, 10. 2. 1 | a number of countries, (i.e. as low as zero or 0.2g/l
92 III, 10. 2. 1 | 16 year olds, lifetime (i.e. at least once in their life)
93 III, 10. 2. 1 | toothpaste has brought – i.e. the reduced incidence and
94 III, 10. 2. 1 | modifiable risk behaviours, i.e. oral hygiene practices,
95 III, 10. 2. 1 | East European countries i.e. Lithuania (37%), Latvia (
96 III, 10. 2. 1 | effects are dose-related, i.e., toothpaste with a higher
97 III, 10. 2. 1 | imbalanced diet. Some of them (i.e. cardiovascular diseases,
98 III, 10. 2. 1 | needs) energy-dense food (i.e. food containing large amounts
99 III, 10. 2. 1 | collected with the same protocol i.e. a single 24-hour recall.
100 III, 10. 2. 1 | to ensure that any claim, i.e.: nutritional, functional
101 III, 10. 2. 1 | marketed 'in dose' form i.e. as pills, tablets, capsules,
102 III, 10. 2. 4 | subgroups of the population (i.e., the identification of high,
103 III, 10. 2. 4 | genomic-environmental pattern: i.e. although having the same
104 III, 10. 2. 4 | individual genomic profiling: i.e., the concurrent detection
105 III, 10. 2. 4 | between predictive tests (i.e., tests with 0-100% probability
106 III, 10. 2. 5 | caregiver(s) (usually mother) i.e, attachment relation, is
107 III, 10. 2. 5 | people only based on age (i.e. young old between 65 and
108 III, 10. 2. 5 | intervention to promote health, i.e. health promoting interventions
109 III, 10. 4. 2 | humans mainly through food (i.e. zoonoses) as a result of
110 III, 10. 4. 2 | Parliament and the Council, i.e. EU Member States). It is
111 III, 10. 4. 2 | so-called ALARA principle, i.e. as low as reasonably achievable,
112 III, 10. 4. 2 | mechanism group” of compounds (i.e. compounds that show dose-addition)
113 III, 10. 4. 2 | respect an absolute value (i.e. public health, consumer
114 III, 10. 4. 2 | Margin of Exposure (MOE), i.e. the point selected on the
115 III, 10. 4. 3 | with a major objective, i.e. to achieve a "good water
116 III, 10. 4. 3 | Guidelines for drinking water, i.e. 10 μg/l (10 ppb).~ ~The
117 III, 10. 4. 4 | and/or consumer services (i.e. tourism services, sports
118 III, 10. 4. 5 | by aquatic or amphibious (i.e moving both on land and
119 III, 10. 4. 5 | possible health effects (i.e. an increase of soft tissues
120 III, 10. 5. 2 | demographic differences as well, i.e. account all analysis for
121 III, 10. 5. 3 | because of CVD morbidity (i.e. 591 days per 1000 population)
122 III, 10. 5. 3 | healthy worker effect’, i.e. that only people in good
123 III, 10. 6. 1 | those ties. Social networks, i.e. social connectedness, make
124 III, 10. 6. 2 | to be structural factors, i.e. conditions in society and
125 IV, 11. 1. 3 | concept of avoidable mortality i.e. mortality which could have
126 IV, 11. 1. 4 | care use and accessibility i.e. to what extent are there
127 IV, 11. 1. 5 | by financial incentives i.e. no linear relationship between
128 IV, 11. 1. 6 | combination of retrospective (i.e. fee-for-service) and prospective (
129 IV, 11. 1. 6 | fee-for-service) and prospective (i.e. capitation, salaries) payment
130 IV, 11. 1. 6 | prospective and may be ‘hard’ (i.e. penalties are incurred for
131 IV, 11. 1. 6 | overspending) or ‘soft’ (i.e. overspending is not penalized).
132 IV, 11. 1. 6 | than the reimbursement, i.e. it may encourage the ‘dumping’
133 IV, 11. 1. 6 | made about outlier cases (i.e. treatment episodes with
134 IV, 11. 1. 6 | higher administrative costs (i.e. Germany, Luxembourg, the
135 IV, 11. 2. 1 | all kind of physicians, i.e. both general practitioners
136 IV, 11. 2. 1 | and surgical specialties (i.e. curing illness and providing
137 IV, 11. 3. 2 | public share of spending i.e. Austria, Belgium, Estonia,
138 IV, 11. 3. 2 | pricing and reimbursement (i.e. the level of public subsidy).
139 IV, 11. 5. 5 | at organizational level, i.e. institute a framework for
140 IV, 11. 6. 2 | be expensive, regressive (i.e. benefits higher income earners
141 IV, 11. 6. 4 | purchasers is capitation (i.e. the amount is determined
142 IV, 11. 6. 4 | use of explicit regulation i.e. a benefits catalogue or
143 IV, 11. 6. 4 | necessary to define indicators, i.e. measures that can be used
144 IV, 11. 6. 4 | to define the benchmark (i.e. the pool of hospitals or
145 IV, 12. 2 | timeframe as well as key tools (i.e. regulations and activity
146 IV, 12. 10 | sexually transmitted diseases (i.e. Hepatitis B & C, HPV, Syphilis,
147 IV, 12. 10 | the regional authorities (i.e. schools, municipalities)
148 IV, 13. 1 | the root causes of health (i.e. health determinants) and
149 IV, 13. 2. 2 | lower-income countries, i.e: estimated to be 2-6% of
150 IV, 13. 2. 3 | highest disease burden, i.e. 9.5%. Estimations of environmental
151 IV, 13. 3 | some 16% of EU citizens, i.e. 78 million people, are at
152 IV, 13. 3 | some 16% of EU citizens, i.e. 78 million people, are at
153 IV, 13. 7. 5 | interpretation of the Directive, i.e. the (im)possibilities for
|
|
| |
